Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Marc Mansour

Professor

University College London

United Kingdom

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Immunology

50%

Cell Biology

50%

Immunotherapy

50%

T Cell Biology

50%

Cancer Biology

50%

Leukemia

30%

Hematology

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles20

Elevated mitochondrial membrane potential is a therapeutic vulnerability in Dnmt3a-mutant clonal hematopoiesis.

Article Link

Year:

2025

Preclinical development of anti-CD21 chimeric antigen receptor T cells to treat T cell acute lymphoblastic leukemia

Article Link

Year:

2025

A modular protein language modelling approach to immunogenicity prediction.

Article Link

Year:

2024

Focal deletions of a promoter tether activate the IRX3 oncogene in T-cell acute lymphoblastic leukemia.

Article Link

Year:

2024

T-ALL and T-LBL: a notch apart.

Article Link

Year:

2024

ToTAL1y degraded - rapid dTAG proteolysis of TAL1 in T-cell acute lymphoblastic leukemia.

Article Link

Year:

2024

Noncoding mutations drive persistence of a founder preleukemic clone which initiates late relapse in T-ALL.

Article Link

Year:

2024

Breaking the performance ceiling for neoantigen immunogenicity prediction

Article Link

Year:

2023

Targeting hyperactive platelet-derived growth factor receptor-β signaling in T-cell acute lymphoblastic leukemia and lymphoma.

Article Link

Year:

2023

The Clinicogenomic Landscape of Induction Failure in Childhood and Young Adult T-Cell Acute Lymphoblastic Leukemia.

Article Link

Year:

2023

Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia

Article Link

Year:

2022

Prognostic value of Oncogenetic mutations in pediatric T Acute Lymphoblastic Leukemia: a comparison of UKALL2003 and FRALLE2000T protocols

Article Link

Year:

2022

Therapeutic targeting of “undruggable” MYC

Article Link

Year:

2022

Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1/PTEN loss

Article Link

Year:

2021

Current and emerging therapeutic approaches for T‐cell acute lymphoblastic leukaemia

Article Link

Year:

2021

Utility of 18F-FDG-PET/CT in lymphoblastic lymphoma

Article Link

Year:

2021

Aging of Preleukemic Thymocytes Drives CpG Island Hypermethylation in T-cell Acute Lymphoblastic Leukemia

Article Link

Year:

2020

CD1a is rarely expressed in pediatric or adult relapsed/refractory T-ALL: implications for immunotherapy

Article Link

Year:

2020

Successful remission induction therapy with gilteritinib in a patient with de novo FLT3‐mutated acute myeloid leukaemia and severe COVID‐19

Article Link

Year:

2020

EZH2-Deficient T-cell Acute Lymphoblastic Leukemia Is Sensitized to CHK1 Inhibition through Enhanced Replication Stress

Article Link

Year:

2020

Collaborators11

Hansen Kosasih

Children's Cancer Institute Australia

AUSTRALIA

Tom Taghon

Professor at Ghent University

Ghent University

BELGIUM

Mark Zimmerman

Dana-Farber Cancer Institute

UNITED STATES

Elspeth Payne

University College London

UNITED KINGDOM

Sine Reker Hadrup

Technical University of Denmark

DENMARK

Rajeev Gupta

University College London

UNITED KINGDOM

David Curtis

MONASH UNIVERSITY

AUSTRALIA

Filip Matthijssens

Ghent University

BELGIUM

Steven Goossens

Professor at Ghent University

Ghent University

BELGIUM

Martin Pule

University College London

UNITED KINGDOM

Sofie Degerman

Umeå University

SWEDEN

How do I reach out?

Meet Kite AI